Descriptive data of antibodies in units transfused to TRALI and control patients
| Antibody . | Units received by control patients (N = 1054) . | Units by TRALI patients (N = 976) . |
|---|---|---|
| Anti-HNA, positive with at least one granulocyte panel cell by GIFT | 6.4% (55/860) | 7.8% (56/714) |
| Anti-HNA, with specificity | 1.7% (15/860) | 1.7% (12/714) |
| Anti–HLA-class I, cognate (MFI > 300) | 11.6% (108/930) | 12.3% (96/782) |
| Anti–HLA-class II, cognate (MFI > 300) | 5.8% (54/930) | 7.8% (61/782) |
| Antibody . | Units received by control patients (N = 1054) . | Units by TRALI patients (N = 976) . |
|---|---|---|
| Anti-HNA, positive with at least one granulocyte panel cell by GIFT | 6.4% (55/860) | 7.8% (56/714) |
| Anti-HNA, with specificity | 1.7% (15/860) | 1.7% (12/714) |
| Anti–HLA-class I, cognate (MFI > 300) | 11.6% (108/930) | 12.3% (96/782) |
| Anti–HLA-class II, cognate (MFI > 300) | 5.8% (54/930) | 7.8% (61/782) |
In 12 TRALI units, there were antibodies to HNA-1a, -1b, or -3a. In 15 control units, there were antibodies to HNA-1a, -1b, -1c, -2a, -3a, or 4a. Using the MFI cut-off of > 300 for determination of anti-HLA specificity, the most common cognate anti–HLA-class I specificities were A2 (15 TRALI units, 11 control units) and B7 (10 TRALI units, 10 control units). The most common DQ specificities were DQ7 (7 TRALI units, 13 control units) and DQ8 (9 TRALI units, 11 control units). The most common DR specificity was DR52 (9 TRALI units, 12 control units).